바이러스 증감제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the global viral sensitizers market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global viral sensitizers market from 2024 to 2031.

Key Insights:

• Viral Sensitizers Market Size (2024E): US$547.4 Mn
• Projected Market Value (2031F): US$1,353.0 Mn
• Forecast Value CAGR (2024 - 2031): 13.8%

Viral Sensitizers Market - Report Scope:

The viral sensitizers market is an emerging sector within the biotechnology and pharmaceutical industries, focusing on agents that enhance the efficacy of viral treatments. These sensitizers are crucial in optimizing therapies such as oncolytic virotherapy, which uses viruses to target and destroy cancer cells, and gene therapy, where they improve the delivery and expression of therapeutic genes. The market is witnessing significant growth driven by advancements in biotechnology, increased investment in cancer research, and the rising prevalence of viral diseases. Additionally, there is a growing trend toward personalized medicine, where sensitizers are tailored to individual patient profiles to maximize treatment outcomes.

Market Growth Drivers:

The global viral sensitizers market is experiencing significant growth, driven by several key factors. One of the primary drivers is the innovation in gene editing technologies, particularly CRISPR-Cas9. These advancements have revolutionized the development of viral sensitizers by allowing precise modifications to viral vectors, enabling them to target specific cells and tissues more effectively while improving their safety profiles. Another major factor contributing to market growth is the advancement in drug delivery technologies, especially the use of nanotechnology, which enhances the efficiency and precision of targeted delivery systems, making viral sensitizers more effective.

Market Restraints:

Despite the promising growth prospects, the viral sensitizers market faces several challenges that could hinder its expansion. One of the key challenges is the technical complexity and manufacturing difficulties associated with the production of viral sensitizers. These biotechnological processes are highly intricate, requiring specialized equipment and expertise, which not only drives up production costs but also extends development timelines. Additionally, manufacturers must navigate stringent regulatory compliance measures to ensure product safety and efficacy. The need for rigorous testing and validation further complicates the process, posing significant hurdles for the timely introduction of new therapies into the market.

Market Opportunities:

The viral sensitizers market offers substantial growth opportunities, particularly through the increasing adoption of combination therapies. By combining viral sensitizers with other therapeutic modalities, such as immunotherapy or targeted therapies, treatment outcomes can be significantly enhanced, providing more effective solutions for complex diseases. Additionally, ongoing research is expanding the therapeutic applications of viral sensitizers beyond oncology. As new mechanisms of action are uncovered, these sensitizers are being explored for the treatment of a broader range of conditions, including infectious diseases and genetic disorders, further driving market growth and innovation.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the viral sensitizers market globally?
• Which applications and technologies are fueling the adoption of viral sensitizers across various sectors?
• How are advancements in biotechnology reshaping the competitive landscape of the viral sensitizers market?
• Who are the key players contributing to the viral sensitizers market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global viral sensitizers market?

Competitive Intelligence and Business Strategy:

Leading players in the global viral sensitizers market focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest heavily in R&D to develop advanced technologies and scalable manufacturing solutions that cater to diverse therapeutic needs. Collaborations with research institutions, regulatory agencies, and healthcare providers facilitate market access and promote technology adoption. Moreover, a strong emphasis on quality assurance and compliance with regulatory standards is critical for sustaining growth in this dynamic market.

Key Companies Profiled:

• Thermo Fisher Scientific
• FUJIFILM Irvine Scientific
• Virica Biotech
• Tocris Bioscience
• Takara Bio Inc.
• ALSTEM
• UniProt
• OZ Biosciences
• Applied Biological Materials
• Virongy Biosciences
• Miltenyi Biotech
• SIRION Biotech
• Boca Scientific
• System Biosciences

Viral Sensitizers Market Segmentation

By Application

• Antiviral Drug Development
• Vaccine Development
• Oncolytic Viral Therapies
• Others

By End User

• Pharmaceutical Companies
• Research Institutes
• Biotechnology Companies
• Others

By Region

• North America
• Europe
• Asia Pacific
• The Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Viral Sensitizers Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Adoption Analysis
• 3.3. Value Chain Analysis
• 3.4. Key Deals and Mergers
• 3.5. PESTLE Analysis
• 3.6. Porter's Five Force Analysis

4. Global Viral Sensitizers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024-2031
• 4.3. Global Viral Sensitizers Market Outlook: Application
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2023
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024-2031
    • 4.3.3.1. Antiviral Drug Development
    • 4.3.3.2. Vaccine Development
    • 4.3.3.3. Oncolytic Viral Therapies
    • 4.3.3.4. Others
• 4.4. Market Attractiveness Analysis: Application
• 4.5. Global Viral Sensitizers Market Outlook: End User
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
    • 4.5.3.1. Pharmaceutical Companies
    • 4.5.3.2. Research Institutes
    • 4.5.3.3. Biotechnology Companies
    • 4.5.3.4. Others
• 4.6. Market Attractiveness Analysis: End User

5. Global Viral Sensitizers Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Viral Sensitizers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 6.2.1. By Country
  • 6.2.2. By Application
  • 6.2.3. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024-2031
  • 6.4.1. Antiviral Drug Development
  • 6.4.2. Vaccine Development
  • 6.4.3. Oncolytic Viral Therapies
  • 6.4.4. Others
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 6.5.1. Pharmaceutical Companies
  • 6.5.2. Research Institutes
  • 6.5.3. Biotechnology Companies
  • 6.5.4. Others
• 6.6. Market Attractiveness Analysis

7. Europe Viral Sensitizers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 7.2.1. By Country
  • 7.2.2. By Application
  • 7.2.3. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkiye
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024-2031
  • 7.4.1. Antiviral Drug Development
  • 7.4.2. Vaccine Development
  • 7.4.3. Oncolytic Viral Therapies
  • 7.4.4. Others
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 7.5.1. Pharmaceutical Companies
  • 7.5.2. Research Institutes
  • 7.5.3. Biotechnology Companies
  • 7.5.4. Others
• 7.6. Market Attractiveness Analysis

8. East Asia Viral Sensitizers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 8.2.1. By Country
  • 8.2.2. By Application
  • 8.2.3. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024-2031
  • 8.4.1. Antiviral Drug Development
  • 8.4.2. Vaccine Development
  • 8.4.3. Oncolytic Viral Therapies
  • 8.4.4. Others
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 8.5.1. Pharmaceutical Companies
  • 8.5.2. Research Institutes
  • 8.5.3. Biotechnology Companies
  • 8.5.4. Others
• 8.6. Market Attractiveness Analysis

9. South Asia & Oceania Viral Sensitizers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 9.2.1. By Country
  • 9.2.2. By Application
  • 9.2.3. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024-2031
  • 9.4.1. Antiviral Drug Development
  • 9.4.2. Vaccine Development
  • 9.4.3. Oncolytic Viral Therapies
  • 9.4.4. Others
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 9.5.1. Pharmaceutical Companies
  • 9.5.2. Research Institutes
  • 9.5.3. Biotechnology Companies
  • 9.5.4. Others
• 9.6. Market Attractiveness Analysis

10. Latin America Viral Sensitizers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 10.2.1. By Country
  • 10.2.2. By Application
  • 10.2.3. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024-2031
  • 10.4.1. Antiviral Drug Development
  • 10.4.2. Vaccine Development
  • 10.4.3. Oncolytic Viral Therapies
  • 10.4.4. Others
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 10.5.1. Pharmaceutical Companies
  • 10.5.2. Research Institutes
  • 10.5.3. Biotechnology Companies
  • 10.5.4. Others
• 10.6. Market Attractiveness Analysis

11. Middle East & Africa Viral Sensitizers Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 11.2.1. By Country
  • 11.2.2. By Application
  • 11.2.3. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024-2031
  • 11.4.1. Antiviral Drug Development
  • 11.4.2. Vaccine Development
  • 11.4.3. Oncolytic Viral Therapies
  • 11.4.4. Others
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 11.5.1. Pharmaceutical Companies
  • 11.5.2. Research Institutes
  • 11.5.3. Biotechnology Companies
  • 11.5.4. Others
• 11.6. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Thermo Fisher Scientific
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. FUJIFILM Irvine Scientific
    • 12.3.2.1. Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Virica Biotech
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. Tocris Bioscience
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Takara Bio Inc.
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. ALSTEM
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. UniProt
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. OZ Biosciences
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. Applied Biological Materials
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. Virongy Biosciences
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. Miltenyi Biotech
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. SIRION Biotech
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Boca Scientific
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy
  • 12.3.14. System Biosciences
    • 12.3.14.1. Overview
    • 12.3.14.2. Segments and Products
    • 12.3.14.3. Key Financials
    • 12.3.14.4. Market Developments
    • 12.3.14.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations